Here's Why You Should Really Own DermTech Stock in 2021
DermTech (NASDAQ: DMTK) is a small cap with a big future. The company has a new diagnostic tool for skin cancer that is easier, cheaper, and far more accurate than the current standard of care.
Right now, diagnosing skin cancer is usually more art than science. A doctor makes a visual assessment of a suspicious mole. To determine a diagnosis, a surgical biopsy must be performed, and another visual assessment made of the mole's cells via a microscope. There's a 17% chance that a doctor using this process will fail to recognize a melanoma.
Source Fool.com